vs
碧迪（BDX）与Cellectis S.A.（CLLS）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Cellectis S.A.的552.6倍（$5.3B vs $9.5M）。碧迪净利率更高（7.3% vs -265.9%，领先273.2%）。Cellectis S.A.同比增速更快（375.0% vs -0.4%）。碧迪自由现金流更多（$549.0M vs $27.6M）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
BDX vs CLLS — 直观对比
营收规模更大
BDX
是对方的552.6倍
$9.5M
营收增速更快
CLLS
高出375.3%
-0.4%
净利率更高
BDX
高出273.2%
-265.9%
自由现金流更多
BDX
多$521.4M
$27.6M
损益表 — Q1 2026 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $9.5M |
| 净利润 | $382.0M | $-25.3M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | -181.1% |
| 净利率 | 7.3% | -265.9% |
| 营收同比 | -0.4% | 375.0% |
| 净利润同比 | 24.0% | -51.9% |
| 每股收益（稀释后） | $1.34 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXCLLS
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.5B | — | ||
| Q1 25 | $5.3B | — | ||
| Q4 24 | $5.2B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.0B | $9.5M | ||
| Q1 24 | $5.0B | — |
净利润BDXCLLS
| Q4 25 | $382.0M | — | ||
| Q3 25 | $493.0M | — | ||
| Q2 25 | $574.0M | — | ||
| Q1 25 | $308.0M | — | ||
| Q4 24 | $303.0M | — | ||
| Q3 24 | $400.0M | — | ||
| Q2 24 | $487.0M | $-25.3M | ||
| Q1 24 | $537.0M | — |
毛利率BDXCLLS
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXCLLS
| Q4 25 | 10.5% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 10.4% | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | 12.1% | -181.1% | ||
| Q1 24 | 14.5% | — |
净利率BDXCLLS
| Q4 25 | 7.3% | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 9.8% | -265.9% | ||
| Q1 24 | 10.6% | — |
每股收益（稀释后）BDXCLLS
| Q4 25 | $1.34 | — | ||
| Q3 25 | $1.71 | — | ||
| Q2 25 | $2.00 | — | ||
| Q1 25 | $1.07 | — | ||
| Q4 24 | $1.04 | — | ||
| Q3 24 | $1.37 | — | ||
| Q2 24 | $1.68 | $-0.28 | ||
| Q1 24 | $1.85 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $149.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $148.6M |
| 总资产 | $54.8B | $407.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXCLLS
| Q4 25 | $740.0M | — | ||
| Q3 25 | $641.0M | — | ||
| Q2 25 | $735.0M | — | ||
| Q1 25 | $667.0M | — | ||
| Q4 24 | $711.0M | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $4.5B | $149.0M | ||
| Q1 24 | $2.3B | — |
股东权益BDXCLLS
| Q4 25 | $25.3B | — | ||
| Q3 25 | $25.4B | — | ||
| Q2 25 | $25.5B | — | ||
| Q1 25 | $25.2B | — | ||
| Q4 24 | $25.2B | — | ||
| Q3 24 | $25.9B | — | ||
| Q2 24 | $25.9B | $148.6M | ||
| Q1 24 | $25.6B | — |
总资产BDXCLLS
| Q4 25 | $54.8B | — | ||
| Q3 25 | $55.3B | — | ||
| Q2 25 | $54.9B | — | ||
| Q1 25 | $54.5B | — | ||
| Q4 24 | $54.7B | — | ||
| Q3 24 | $57.3B | — | ||
| Q2 24 | $55.6B | $407.1M | ||
| Q1 24 | $54.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $27.6M |
| 自由现金流率自由现金流/营收 | 10.5% | 290.5% |
| 资本支出强度资本支出/营收 | 2.1% | 13.2% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXCLLS
| Q4 25 | $657.0M | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $164.0M | — | ||
| Q4 24 | $693.0M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.3B | $28.9M | ||
| Q1 24 | $514.0M | — |
自由现金流BDXCLLS
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $588.0M | — | ||
| Q3 24 | $882.0M | — | ||
| Q2 24 | $1.1B | $27.6M | ||
| Q1 24 | $380.0M | — |
自由现金流率BDXCLLS
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 16.2% | — | ||
| Q2 24 | 22.4% | 290.5% | ||
| Q1 24 | 7.5% | — |
资本支出强度BDXCLLS
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 3.6% | 13.2% | ||
| Q1 24 | 2.7% | — |
现金转化率BDXCLLS
| Q4 25 | 1.72× | — | ||
| Q3 25 | 2.75× | — | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
CLLS
暂无分部数据
